Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Obstructive Sleep Apnoea
Interventions
DRUG

Carbocysteine

carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.

DEVICE

Continuous Positive Airway Pressure

Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .

Trial Locations (1)

510120

Guangzhou institute of respiratory disease, Guangzhou

All Listed Sponsors
lead

Guangzhou Institute of Respiratory Disease

OTHER

NCT02015598 - Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome | Biotech Hunter | Biotech Hunter